Scholar Rock updates apitegromab BLA progress, starts FSHD Phase 2 trial
The company reported two active fill-finish supply paths for its SMA drug ahead of a September 30 PDUFA date and disclosed $492 million in cash as of June 30, 2026.
SEC filing
Latest
2 stories
Thursday, August 6
Scholar Rock refiles at-the-market offering for up to $200 million
The company superseded its November 2025 sales agreement prospectus, with shares closing at $45.85 on August 3, 2026.
SEC filing